A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of avonex in patients with multiple sclerosis
- 1 April 2004
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 26 (4) , 511-521
- https://doi.org/10.1016/s0149-2918(04)90053-7
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: